Correction to: Impact of molecular tumour board discussion on targeted therapy allocation in advanced prostate cancer

Br J Cancer. 2022 Apr;126(7):1108. doi: 10.1038/s41416-022-01765-y.

¹ Radboud University Medical Centre, Radboud Institute for Health Sciences, Department of Medical Oncology, Nijmegen, The Netherlands.
² Radboud University Medical Centre, Radboud institute for Molecular Life sciences, Department of Experimental Urology, Nijmegen, The Netherlands.
³ Radboud University Medical Centre, Radboud Institute for Health Sciences, Department of Urology, Nijmegen, The Netherlands.
⁴ Radboud University Medical Centre, Radboud Institute for Molecular Life sciences, Department of Pathology, Nijmegen, The Netherlands.
⁵ Radboud University Medical Centre, Radboud Institute for Molecular Life sciences, Department of Human Genetics, Nijmegen, The Netherlands.
⁶ Radboud University Medical Centre, Radboud Institute for Health Sciences, Department of Medical Oncology, Nijmegen, The Netherlands. Niven.Mehra@radboudumc.nl.

No abstract available

Publication types